Lilly's ramu' has squamous, non-squamous potential

Share this article:
Eli Lilly
Eli Lilly

Eli Lilly's Phase III results for its pipeline oncology drug ramucirumab show the company may open up financial and treatment possibilities among non-small cell lung cancer (NSCLC) patients.

The test included second-line squamous and non-squamous NSCLC patients who were treated with either ramucirumab and docetaxel, or placebo and docetaxel. The company said in a statement that there was “statistically significant improvement in the primary endpoint for overall survival” in the plus-ramucirumab group vs. placebo, as well as a “statistically significant improvement” in progression-free survival in the plus-ramucirumab vs. the chemotherapy-only groups.

This is good news in terms of endpoints, but analysts are divided about what this means in terms of potential market share. The key is Roche's Avastin, which is currently approved for first-line non-squamous NSCLC.

ISI Group analyst Mark Schoenebaum noted in his Wednesday reaction that Roche estimates its share of the US non-squamous NSCLC market is 35% to 40% and that Lilly pegs it at around 20%. Schoenebaum says a non-squamous approval puts Lilly's potential at around $750 million.

Bernstein's Tim Anderson is more optimistic about Lilly's opportunity in the non-squamous market. His reason, as noted in his February 19 analysis, is that “most patients with NSCLC fail whatever first-line therapy they may be receiving,” and the analyst sees a potential $1-billion windfall in this one-treatment scenario.

The squamous setting is a significant opportunity, and both analysts note that Lilly left out some critical information in Wednesday's release, such as what the overall- and progression-free survival came down to in terms of time as well as how many of the Phase-III REVEL patients were non-squamous and how many were squamous.

Schoenebaum described the squamous market as “wide open” with the potential to hit $1 billion. The key is again Avastin, which he notes cannot be prescribed for squamous patients “because of severe bleeding in the lungs.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...